Artiva Biotherapeutics Strengthens Board Alignment with New Director Stock Options

Rhea-AI Filing Summary

Director Brian Daniels of Artiva Biotherapeutics was granted stock options on June 24, 2025. The key details of this insider transaction include:

• Received 13,750 stock options to purchase common stock
• Exercise price set at $1.61 per share
• Options will expire on June 23, 2035
• Vesting schedule: 100% vesting on the earlier of June 24, 2026, or the date of the 2026 annual stockholder meeting

This grant appears to be part of the company's director compensation program. The transaction was reported via Form 4 filing and executed through an attorney-in-fact, Neha Krishnamohan. The options represent a new position for the director, as no prior holdings were reported in the filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DANIELS BRIAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	13,750	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 13,750 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DANIELS BRIAN

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$1.61	06/24/2025		A		13,750		(1)	06/23/2035	Common Stock	13,750	$0	13,750	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.

	/s/ Neha Krishnamohan, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options were granted to Brian Daniels at ARTV on June 24, 2025?

Brian Daniels was granted 13,750 stock options (Right to Buy) with an exercise price of $1.61 per share. These options were granted on June 24, 2025, and will expire on June 23, 2035.

What is the vesting schedule for Brian Daniels' ARTV stock options granted in June 2025?

The stock options will vest in full on the earlier of June 24, 2026, or the date of Artiva Biotherapeutics' 2026 annual stockholder meeting.

What position does Brian Daniels hold at ARTV according to the Form 4?

According to the Form 4 filing, Brian Daniels serves as a Director at Artiva Biotherapeutics (ARTV). This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What is the total value of ARTV stock options granted to Brian Daniels in this Form 4?

The Form 4 shows that Brian Daniels received 13,750 stock options with an exercise price of $1.61 per share. The options were granted at $0 cost to Daniels, as indicated in the 'Price of Derivative Security' column.